Prescient Therapeutics Ltd
F:UDD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Prescient Therapeutics Ltd
F:UDD
|
AU |
|
Central Pattana PCL
OTC:CPPBY
|
TH |
|
C
|
China Overseas Land & Investment Ltd
XMUN:CPP
|
HK |
Intrinsic Value
The intrinsic value of 
Prescient Therapeutics Ltd (UDD) under the Base Case is 0.02 EUR per share.
Compared with the current market price of 0.11 EUR, the stock appears
Overvalued by 84% .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Prescient Therapeutics Does
Prescient Therapeutics Ltd is a clinical-stage biotechnology company focused on cancer treatments. It develops cell-based and targeted therapies designed to help the immune system attack cancer cells or make tumors more vulnerable to treatment. Its work is aimed at cancers with strong unmet medical need, especially where standard treatments have limited effect or resistance can build over time.
- Headquarters
- Australia AU
- IPO date
- Dec 19, 1986
Earnings Waterfall
Prescient Therapeutics Ltd
The intrinsic value for Prescient Therapeutics Ltd (UDD) under the Base Case is 0.02 EUR.
Compared with the current market price of 0.11 EUR, the stock appears Overvalued by 84% .